FDA Lifts Black Box Warning on Menopause HRT
In a landmark shift, the FDA announced on November 10, 2025, the removal of its stringent “black box” warning from hormone replacement therapy (HRT) products for menopausal symptoms. This reverses a 20+ year policy rooted early-2000s studies that overstated risks like breast cancer and heart disease.
As a provider, this not only reduces regulatory constraints on administration of the treatment, but it opens the door for greater access to treatment with less scrutiny. This is an important development that requires changes to your consent forms and discussions with patients prior to receiving this treatment.
Key Takeaways:
Basis for Change: An expert panel’s review of modern data emphasizes HRT’s net benefits when initiated before age 60 or within 10 years of menopause onset—highlighting design flaws in prior trials.
Industry Impact: The American College of Obstetricians and Gynecologists President noted improved access via shared decision-making, without “unnecessary barriers.” Although risks remain, prescriptions require individualized doctor-patient discussions.
Labeling and disclaimers should be changing rapidly in the coming months. This precedent underscores liability risks in outdated regulatory warnings and opportunities in informed consent litigation. Clinicians should review their protocols and education on nuanced prescribing while watching for evolving malpractice standards in women’s health.
At OLKM, we’re here to help you understand these changes and how to implement them in your practice.
